SEARCH

SEARCH BY CITATION

References

  • 1
    Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010; 50: 295322.
  • 2
    Cryan JF, O'Leary OF. Neuroscience. A glutamate pathway to faster-acting antidepressants? Science 2010; 329: 913914.
  • 3
    Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 7: 426437.
  • 4
    Murrough JW, Charney DS. Cracking the moody brain: lifting the mood with ketamine. Nat Med 2010; 16: 13841385.
  • 5
    Krystal JH. N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants. Arch Gen Psychiatry 2010; 67: 11101111.
  • 6
    Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010; 13: 7182.
  • 7
    Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 29212927.
  • 8
    Naskar R, Vorwerk CK, Dreyer EB. Concurrent downregulation of a glutamate transporter and receptor in glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 19401944.
  • 9
    Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 270276.
  • 10
    Anand A, Gunn AD, Barkay G, Karne H, Nurnberger JI, Mathew SJ, Ghosh S. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2012; 14: 6470.
  • 11
    Hamilton M. Hamilton depression scale. In: ECDEDU Assessment Manual for Psychopharmacology, Revised Edition, ed. Guy W . Rockville, MD: National Institute of Mental Health, 1976; 179192.
  • 12
    Storosum JG, Elferink AJ, van Zwieten BJ. Schizophrenia: do we really need placebo-controlled studies? Eur Neuropsychopharmacol 1998; 8: 279286.
  • 13
    Gomeni R, Merlo-Pich E. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol 2007; 63: 595613.
  • 14
    Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10: 325337.
  • 15
    Cleveland WS, Devlin SJ. Locally weighed regression: an approach to regression analysis by local fitting. J Am Stat Assoc 1988; 83: 596610.
  • 16
    Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B Stat Methodol 2002; 64: 583639.
  • 17
    Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998; 7: 434455.
  • 18
    Pilla Reddy V, Kozielska M, Johnson M, Vermeulen A, de Greef R, Liu J, Groothuis GMM, Danhof M, Proost JH. Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet 2011; 50: 429450.
  • 19
    Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115127.